We have previously shown that activation of cellautonomous innate immune signaling facilitates the transdifferentiation of fibroblasts into induced endothelial cells, and is required to generate induced endothelial cells with high fidelity for endothelial lineage. Recent studies indicate that a glycolytic switch plays a role in induced pluripotent stem cell generation from somatic cells.
T
he fluidity of adult cell fate was first shown by using nuclear transfer or cell fusion. 1, 2 Decades later, Yamanaka and colleagues transformed fibroblasts into induced pluripotent stem cells by the forced expression of 4 transcription factors (Oct 4, Sox2, KLF4, and cMYC). 3 Patient-specific induced pluripotent stem cellderived cells are now used to understand the mechanisms of pluripotency; to elucidate pathobiology 4, 5 ; to perform high-throughput screens for new therapies 6 ; and to generate materials for regenerative cell therapy. 7 Yamanaka's discovery precipitated a spirited search for combinations of transcriptional or epigenetic factors, or small molecules, that could transform one somatic cell into another type of somatic cell. A flurry of reports provided evidence that, indeed, a handful of lineage-specific transcriptional factors can directly reprogram fibroblasts into a different somatic cell type, such as neurons, 8, 9 cardiomyocytes, 10, 11 hepatocytes, 12 and endothelial cells. 13 Subsequently, we provided evidence that nuclear reprogramming to pluripotency 14 or direct reprogramming to another cell lineage 15 requires cell-autonomous innate immune signaling and activation of NF-κB and IRF3. This inflammatory signaling cascade downregulates histone deacetylase and upregulates histone acetyltransferases (HATs), 14 increasing histone acetylation and DNA accessibility. Furthermore, activation of innate immunity increases the nuclear levels of inducible nitric oxide synthase (NOS) that binds to and S-nitrosylates the repressive polycomb complex 1, thereby reducing suppressive histone markings. 16 Recent studies have revealed that the generation of induced pluripotent stem cells from somatic cells is accompanied by a glycolytic shift. 18, 19 Specifically, somatic cells switch from primary use of oxidative phosphorylation for ATP generation to glycolysis during the transformation to pluripotent cells. Nuclear reprogramming to pluripotency may be more efficient if the metabolic profile of the starting somatic cells is similar to the glycolytic state observed in pluripotent cells. 20, 21 Furthermore, an increase in cytosolic acetyl coenzyme A (acetyl-CoA) synthesis is thought to maintain the histone acetylation required for pluripotency. 22 Accordingly, we were interested to determine if a glycolytic switch might occur during transdifferentiation of one somatic cell to another somatic cell lineage.
In this study, we confirm that activation of innate immunity is required for transdifferentiation, and is associated with a glycolytic shift. This glycolytic switch is accompanied by an increased expression of the mitochondrial citrate transporter. The resulting increase of intracellular citrate together with an increased nuclear expression of ATP-citrate lyase (ACL; converts citrate to acetyl-CoA), supplies acetyl-CoA, thereby supporting the observed increase in HAT activity and histone acetylation. Inhibition of these metabolic processes abrogates the transdifferentiation of fibroblasts to endothelial cells. These data indicate a direct metabolic coupling to epigenetic events that increase DNA accessibility and facilitate nuclear reprogramming.
METHODS
The data, analytic methods, and study materials will be made available to other researchers from the corresponding author on reasonable request for purposes of reproducing the results or replicating.
Experimental Animals
All animals were maintained in a specific pathogen-free facility at Houston Methodist Research Institute in Houston. Animal use and care were approved by the Houston Methodist Animal Care and Use Committee in accordance with institutional animal care and use guidelines. SCID NOD mice were purchased from Jackson Laboratory.
In Vitro Transdifferentiation
In vitro transdifferentiation was conducted as previously described. 15 BJ fibroblast cells (1×10   4   ) were seeded in gelatincoated 6-well plates. Poly I:C (30 ng/mL) was applied with induction medium for the first week. In the second week, cells were exposed to vascular endothelial growth factor (50 ng/ mL), basic fibroblast growth factor (20 ng/mL), bone morphogenetic protein 4 (20 ng/mL), and 8-bromoadenosine 3ʹ,5ʹ-cyclic monophosphate (100 μmol/L) in EGM medium. Then the CD31+ cells were analyzed or sorted with flow cytometer. The sorted cells were cultured and expanded in EGM medium with SB431542 (10 μmol/L).
In Vivo Transdifferentiation
Matrigel (500 μL) was mixed with green fluorescent protein (GFP)-labeled BJ fibroblasts (1×10 6 ) and our transdifferentiation
Clinical Perspective
What Is New?
• A glycolytic shift is required for transdifferentiation of fibroblasts to endothelial cells.
• The glycolytic shift supplies more citrate to the nucleus, where it is converted to acetyl-coenzyme A.
• Acetyl-coenzyme A is a substrate for histone acetylation, increasing DNA accessibility.
What Are the Clinical Implications?
• Transdifferentiation of fibroblasts to endothelial cells could increase microvascular density, improve perfusion, and reduce tissue fibrosis.
• An understanding of underlying mechanisms may lead to therapeutic transdifferentiation for ischemic syndromes, so as to enhance perfusion, reduce scar formation, and provide a microvascular niche for tissue regeneration.
Circulation. ORIGINAL RESEARCH ARTICLE formulation (30 ng/mL poly I:C + 50ng/mL vascular endothelial growth factor + 20 ng/mL basic fibroblast growth factor + 20 ng/mL bone morphogenetic protein 4 + 100 μmol/L 8-bromoadenosine 3ʹ,5ʹ-cyclic monophosphate + 10 μmol/L SB431542) with or without pharmacological modulators of glycolysis. The mixture was injected subcutaneously into the abdomen of the SCID NOD mice (2 months old; Jackson Laboratories). The Matrigel plugs were harvested 14 days after injection. The plugs were dissolved with Dispase I (2 mg/mL), and the cells isolated were analyzed by flow cytometry, and the percentages of GFP+ and human CD31+ cell were quantified. The investigator who analyzed the Matrigel plugs was blinded to the initial treatment.
Flow Cytometry
Cells were stained with CD31 antibody and 4′,6-diamidino-2-phenylindole, and the cell population was gated based on nonstaining and 4′,6-diamidino-2-phenylindole-staining controls. The data were recorded by BD FACSDiva software and analyzed by FlowJ software.
Seahorse Assay
BJ fibroblasts (3×10 4 ) were seeded into each well of Seahorse XF24 Cell Culture Microplates, for observation of metabolic parameters during transdifferentiation. For Mito stress assay, cells were exposed to sequential treatments with oligomycin (1 μm), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (1 μm), and rotenone/antimycin A (0.5 μm). The oxygen consumption rate (OCR; an index of oxidative phosphorylation) was recorded by XF-24 Extracellular Flux Analyzer (Seahorse Bioscience). Basal OCR refers to the OCR level before oligomycin injection. For the glycolysis stress assay, cells were exposed to glucose (10 mm), oligomycin (1 μm), and 2-deoxy-d-glucose (50 mm), and then the extracellular acidification rate (ECAR; an index of glycolysis) was recorded. ECAR capacity refers to the increase of ECAR after mitochondrial inhibition.
Glucose Uptake and Lactate Production Assay
Culture medium was collected 24 hours after fresh medium had been added. The concentration of glucose and lactate in the cell medium were assessed with Glucose uptake assay kit and Lactate assay kit (Cayman Chemical) following the manufacturer's instructions.
U 13 C-Glucose Metabolix Flux Assay
Cells were starved with glucose-free medium overnight and were cultured in the presence of U 13 C-glucose or 12 C-glucose (10 mmol/L) control medium for 3 hours, then the metabolites from the cells were extracted and analyzed by liquid chromatography-mass spectrometry for mass isotope distribution performed by Metabolomics core of Baylor College of Medicine.
Quantitative Reverse Transcription Polymerase Chain Reaction
RNA was extracted with RNeasy Kit (Qiagen), and cDNA was synthesized with qScript XLT cDNA SuperMix (Quanta Biosciences). SYBR Green method and QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems) were used for quantitative reverse transcription polymerase chain reaction with primers listed below. The expression of mRNA was normalized to that of mRNA encoding 18S. 
Primers

Acetyl-CoA Fluorometric Assay
Cell samples were deproteinized with a perchloric acid/ KOH protocol to remove enzymes in the samples, then acetyl-CoA concentration was measured with acetyl-CoA fluorometric assay kit (Biovision K317) following the manufacturer's instructions. In brief, the free CoA in the samples was quenched, then the CoA converted from acetyl-CoA will form NADH which interacts with PicoProbe, then the concentration of acetyl-CoA can be reflected by the fluorescence from the PicoProbe (excitation/emission=535/587 nm).
Immunofluorescence Staining
Cells seeded and treated on the Laboratory-Teck chamber slides were fixed with 4% paraformaldehyde for 10 minutes, then the slides were permeabilized by 0.1% Triton X-100 for 10 minutes, then blocked with bovine serum albumin for 1 hour at room temperature. The slides were then incubated with ACL antibody overnight at 4°C. On the following day, the slides were incubated with secondary antibody for 1 hour at room temperature and mounted. Microphotographs were taken using 40× magnification and a Leica upright fluorescent microscope.
HAT Activity Assay
Total histone proteins were extracted with the EpiQuik Total Histone Extraction Kit and were loaded in the strip wells where unique histone substrates were precoated. Then the active HATs within the histone proteins bound and acetylated the histone substrate, which can be recognized with antiacetylated histone antibody. The HAT enzyme activity, proportional
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to the ratio or the amount of the acetylated histone, was further colorimetrically quantified through an ELISA-like reaction.
Tetramethylrhodamine Mitochondrial Potential Assay
Cells were stained with tetramethylrhodamine (20 nmol/L) for 30 minutes and the fluorescent signal was detected by flow cytometry.
Mitochondrial DNA Content Measurement
Total DNA was analyzed by real-time quantitative polymerase chain reaction for mitochondrial gene ND1 and nuclear gene RPLP0. The ratio of the relative levels of ND1 and RPLP0 reflected mitochondrial DNA content.
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ACL Knockdown
BJ fibroblast cells were transfected with siControl or siACL (2500 ng) using lipofectamine 3000. We used an siRNA pool (SMARTpool: ON-TARGETplus ACLY siRNA, Dharmacon, L-004915-00-0005) which is a mixture of 4 siRNA constructs provided as a single reagent. Then the cells were seeded for in vitro transdifferentiation 72 hours posttransfection or used for evaluation of knockdown efficiency.
Fatty Acid Uptake Assay
The cells were incubated with BODIPY-dodecanoic acid fluorescent fatty acid analog and fatty acid uptake was measured in a kinetic reading mode for 30 minutes. The relative fluorescence units was recorded every 20 seconds with the excitation filter of 470 to 500 nm and an emission filter of 500 to 560 nm.
Nile Red Staining
Cells were fixed with 4% paraformaldehyde and stained with Nile red (0.05 μg/mL) for 30 minutes. Then the cells were imaged with Leica upright fluorescent microscope at 10× magnification.
Reagents
FBPase-1 inhibitor was purchased from Alfa Aescar; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3-PO) was purchased from Calbiochem; 2-deoxy-d-glucose, sodium oxamate, sodium dichloroacetate, Dispase I, and Nile red were purchased from Sigma; CPI613, anacardic acid, BMS303141, SB204990, 8-bromoadenosine 3ʹ,5ʹ-cyclic monophosphate, and SB431542 were purchased from Tocris Bioscience. Poly I:C was from InvivoGen; vascular endothelial growth factor, fibroblast growth factor, bone morphogenetic protein 4 were from Pepro Tech. U 13 C-Glucose was from Cambridge Isotope Laboratories. Human-specific CD31 was purchased from BD, ACL antibody used for immunofluorescence was from Thermo Fisher, SLC25A1 antibody was from Proteintech, and the other antibodies were from Cell Signaling Technology. Tetramethylrhodamine was from Invitrogen. siControl and siACL were from Dharmacon. Lipofectamine 3000 transfection reagents were from Invitrogen. Oxidative stress and glycolytic stress assays were purchased from Seahorse Bioscience. Growth factor-reduced Matrigel was from BD. Glucose uptake and lactate production assay kits were from Cayman Chemical. The Nuclear/Cytosol fraction kit was from BioVision.
The HAT activity assay kit was from EpiGentek. QBT fatty acid uptake assay kit was from Molecular Devices.
Statistical Analysis
All results are shown as mean value along with ± SEM of 2 to 5 biological replicates. For comparison between 2 groups, P values were determined by using the Student t test. For multiple comparisons, 1-way ANOVA was used, with P value further corrected by using the Dunnett method (*, 0.01 <P<0.05; **, 0.001<P<0.01; ***, P<0.001).
RESULTS
Glycolytic Switch Occurs at the Onset of Transdifferentiation
We have previously established a nonviral method to transdifferentiate fibroblasts to induced endothelial cells (iECs). 15 We activate innate immune signaling with the toll-like receptor 3 (TLR3) agonist poly I:C for 7 days followed by the addition of growth factors that favor endothelial lineage for another 7 days (Figure IA in the online-only Data Supplement). This protocol generates a yield of 2% to 5% iECs from parental fibroblasts (representative data shown in Figure IB in the online-only Data Supplement). The yield of iECs from our small molecule-based approach is low in comparison with transdifferentiation methods using viral vectors. 10 However, our yield is similar to other chemical-based methods to induce transdifferentiation. 17 Furthermore, the iECs that we obtain with our method are highly similar to authentic endothelial cells by immunohistochemical, functional, and transcriptional profiles. 15 Because glycolytic metabolism appears to be necessary to maintain pluripotency, 21 we hypothesized that a glycolytic switch may occur during transdifferentiation. Accordingly, we performed Seahorse flux analysis to assess the OCR and lactate production as assessed by the ECAR. Within 6 days of initiating the transdifferentiation protocol, and before adding the endothelial growth factors, we observed significant and reproducible decreases in basal OCR, oxygen usage devoted to ATP production, and maximal respiration capacity ( Figure 1A and 1B) . In concert, we observed increases in basal ECAR, glycolysis capacity, and glycolytic reserve ( Figure 1C and 1D) . Furthermore, the transition to a glycolytic state happened as early as 3 days after exposure to the innate immune activator poly I:C, and well before we observed iECs (at 2 weeks). To confirm the metabolic switch, we measured glucose uptake ( Figure 1E ) and lactate production ( Figure 1F ). We observed that both the glucose uptake and lactate production increased early in the transdifferentiation process, consistent with a glycolytic shift. (Figure 2A ). Inhibitors were added on days 0 to 3 of the transdifferentiation protocol. After completion of the 2-week protocol for transdifferentiation, we assessed the yield of iECs using flow cytometry with CD31 antibodies. We observed that stimulators of glycolysis (FBPase1 inhibitor and CPI613) increased the iEC yield, 
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whereas the inhibitors of glycolysis (2-deoxy-d-glucose, 3PO, oxamate, or sodium dichloroacetate) decreased the yield of iECs ( Figure 2B ). To determine if transdifferentiation of human fibroblasts to iECs could be observed in vivo, and was dependent on a glycolytic shift, we used the Matrigel plug model. We mixed GFP-labeled human (BJ) fibroblasts (1×10 6 ) with growth factor-reduced Matrigel (500 μL) together with our transdifferentiation formulation (poly I:C, vascular endothelial growth factor, fibroblast growth factor, bone morphogenetic protein 4, 8-bromoadenosine 3ʹ,5ʹ-cyclic monophosphate, and SB431542, as previously described 16 ). In some formulations, FBPase inhibitor (10 μm) or CPI613 (120 μm) was added to the Matrigel. The Matrigel was subcutaneously injected into SCID mice. After 2 weeks, the Matrigel plugs were harvested and digested for analysis of iEC generation using flow cytometry and human-specific CD31 antibodies (specificity of the antibody was confirmed using human or murine microvascular endothelial cells; Figure II in the online-only Data Supplement). In the presence of the transdifferentiation formulation, a small percentage of GFP-labeled human fibroblasts transdifferentiated into CD31+ cells. The yield of GFP+/CD31+ cells increased with coadministration of either of the glycolysis enhancers ( Figure 2C and  2D) . Taken together, our data showed that the promoters of glycolytic metabolism enhanced, whereas the inhibitors of glycolysis impaired, transdifferentiation in vitro and in vivo. To our knowledge, this is the first evidence that transdifferentiation of one somatic cell to another requires a glycolytic shift.
Innate Immune Signaling Induces a Glycolytic Switch
Our previous work shows that innate immune activation is required for transdifferentiation. 15 Because the metabolic profiling data suggested that the glycolytic switch occurred early in our transdifferentiation protocol, before we administered the growth factors promoting endothelial lineage, we hypothesized that innate immune signaling alone might be responsible for the glycolytic switch. Accordingly, we treated BJ fibroblasts for 3 days with the TLR3 agonist poly I:C (30 ng/mL) and assessed cellular metabolism by Seahorse assays. Short-term treatment with poly I:C increased ECAR ( Figure 3A and 3B) and decreased OCR ( Figure 3C and  3D) . Thus, innate immune activation alone initiates the glycolytic switch, which is accompanied by increased lactate production ( Figure 3E ). The hypothesis was further validated by mitochondrial membrane potential measurements using tetramethylrhodamine staining. To further elucidate the mechanisms by which innate immune signaling induces glycolysis, we assessed the effect of poly I:C stimulation on glycolysis-related gene and protein expression. Our data revealed that the major regulators for glycolysis were all affected by innate immune activation at both gene ( Figure 3F through 3K ) and protein expression levels ( Figure 3L ) with changes mirroring the increased glycolysis. For example, the HK2, PFKFB3, and LDHA enzymes that facilitate glycolysis were positively regulated by poly I:C. Conversely, FBP1 and PDH (that act to restrain glycolysis) were negatively regulated. These data support our hypothesis that cell-autonomous innate immune signaling activates a glycolytic switch.
Innate Immune Signaling Increases Citrate Accumulation
As observed in Figure 3 , the modest increase in lactate production did not fully explain the sharp rise in ECAR after poly I:C activation. To further clarify the metabolism of glucose, we used carbon 13-labeled glucose, U 13 C-glucose, for metabolic flux assays. By comparison with vehicle controls, exposure to the TLR3 agonist significantly increased U 13 C-citrate levels. However, there were no significant changes in U 13 Clabeled succinate or fumarate and a slight reduction in U 13 C-labeled α-ketoglutarate and malate ( Figure 4A ). Furthermore, we did not observe significant changes in tricarboxylic acid cycle (TCA cycle) enzymes (Figure IV in the online-only Data Supplement). Thus, the elevated citrate levels were not associated with concomitant increases in other intermediates within the TCA cycle. These observations could be explained if there was an increase in transport of citrate out of the mitochondria. Indeed, we observed that citrate transporter Slc25a1 was increased at the levels of mRNA ( Figure 4B ) and protein expression ( Figure 4C ). In aggregate, these data suggest that innate immune signaling facilitates the transport of citrate out of the mitochondria. Thus, the glycolytic switch is characterized by an increase in glycolysis, a reduction in oxidative phosphorylation (eg, TCA cycle activity), and an export of some citrate out of the TCA cycle.
Innate Immune Signaling Promotes the Use of Citrate in Histone Protein Acetylation
After citrate is exported out of the mitochondria, it may be converted into acetyl-CoA by cytoplasmic ACL, and used for fatty acid synthesis. Accordingly, we assessed fat levels using Nile red staining ( Figure VA in the online-only Data Supplement). We observed no significant change with poly I:C treatment indicating that activation of innate immune signaling had no significant effect on fatty acid production in the cytoplasm.
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Citrate also serves as a precursor for acetyl-CoA in the nucleus. Nuclear acetyl-CoA is a substrate for HATs to acetylate histone proteins, thereby increasing DNA accessibility. 25 Nuclear acetyl-CoA can be derived from the activity of ATP-citrate lyase (ACL), acetyl-CoA synthetase (ACSS2), 26 or PDH. 27 It is intriguing that poly I:C increased ACL gene expression ( Figure 5A ), and increased levels of acetyl-CoA ( Figure 5B ), as well, in fibroblasts. In human fibroblasts, the expression of ACSS2 gene was not detectable in the presence or absence of Because ACL is compartmentalized in both the cytoplasm and the nucleus, 29 we assessed changes in ACL 13 C (n) indicates the number (n) of 13 C atoms incorporated into the metabolites. Y axis shows the percentages of relative abundance of each 13 C (n) metabolites (n=2). B, RNA levels of Slc25A1 are enhanced by poly I:C (normalized with 18S, n=3). C, Protein levels of Slc25A1 are enhanced by poly I:C (normalized with β-actin, n=3) (*0.01 <P<0.05; **0.001<P<0.01). ACO indicates Aconitase; CS, Citrate synthase; FH, fumarate hydratase; α-KG, α-ketoglutarate; KGDH, α-ketoglutarate dehydrogenase; LC-MS, liquid chromatographymass spectrometry; MDH, malate dehydrogenase; SDH, succinate dehydrogenase; and TCA, tricarboxylic acid cycle. localization in treated fibroblasts. We observed that poly I:C increased nuclear levels of ACL with no change in cytoplasmic ACL levels ( Figure 5C ). Immunofluorescence studies confirmed a distinct increase in nuclear ACL after poly I:C treatment ( Figure 5D ). Together, these observations suggested that the changes in acetyl-CoA that were induced by innate immune signaling are dependent on nuclear ACL.
Acetyl-CoA generated by ACL is essential for histone protein acetylation. 25, 30 Accordingly, we assessed HAT activity in the presence or absence of poly I:C stimulation. We observed that HAT activity was significantly augmented in the poly I:C-treated cells ( Figure 5E ). To determine if the increase in HAT activity was associated with epigenetic changes, we assessed acetylation of H3K9, H3K27, and H3K14. All were increased with poly I:C stimulation ( Figure 5F ). It is notable that inhibition of HAT activity by anacardic acid (50 μm), impaired transdifferentiation, as reflected by a reduction in the yield of iECs from our transdifferentiation protocol ( Figure 5G ).
Taken together, these data suggested that citrate exported out of the mitochondria is preferentially shunted to the nucleus where it serves as the precursor for acetyl-CoA, and thereby facilitates histone acetylation. The increases in HAT activity appear to facilitate histone acetylation and transdifferentiation. 
ACL Knockdown Impairs Transdifferentiation
Because ACL is a key enzyme that links metabolism with histone acetylation, 29 we next determined the direct role of ACL in transdifferentiation. We first used 2 specific inhibitors for ACL, BMS303141 (50 μm) and SB204990 (10 μm). Each of these inhibitors reduced the yield of iECs from fibroblasts in our transdifferentiation protocol ( Figure 6A ). However, we understand that most drugs have off-target effects, so we confirmed our results using siRNA ACL knockdown ( Figure VIA and IVB in the online-only Data Supplement). The siRNA data were consistent with that obtained using BMS303141 or SB-204990 ( Figure 6B ). Because ACL expression is important for glycolysis in other contexts, 31 we assessed its role in the glycolysis triggered by innate immune activation. Using Seahorse technology, we observed that siRNA knockdown of ACL markedly reduced the glycolytic shift induced by poly I:C, as evidenced by an attenuation of ECAR in the siACL group in comparison with siControl ( Figure 6C and Figure VIC in the online-only Data Supplement). Intriguingly, when we treated cells with the LDHA inhibitor oxamate to block the glycolytic switch or hexokinase inhibitor 2DG to block glycolysis, we observed a reduction in the expression of nuclear ACL ( Figure 6D and Figure VID in the online-only Data Supplement). These data indicate a reciprocal relationship between nuclear ACL expression and glycolysis in transdifferentiation.
DISCUSSION Overview
In this article, we report the exciting new observation that transdifferentiation requires a glycolytic shift that couples metabolism to epigenetic plasticity. We have discovered that the glycolytic shift, together with an increase in nuclear ACL, increases nuclear acetyl-coA, to support the increased expression and activity of HAT. What is gained with this knowledge is a greater understanding of the mechanisms of transdifferentiation, and a potential therapeutic avenue, as well. Furthermore, in an era where pharmaceutical companies are exploring the use of glycolytic inhibitors for patients with insulin resistance, it is important to be aware of how these drugs may influence a process that could alter a patient's response to ischemia or tissue injury.
Transdifferentiation Requires a Glycolytic Shift
Prior work has linked metabolism to epigenetic modulation in stem cell biology 32 and in malignancy where the glycolytic shift is also known as the Warburg effect. 33 Here, we provide the first demonstration that a glycolytic shift is required for transdifferentiation of a somatic cell to another cell lineage. Antagonists of glycolytic metabolism suppress, whereas antagonists of oxidative phosphorylation augment, the yield of iECs in response to the transdifferentiation protocol. We also find that activation of cell-autonomous innate immune signaling is the key step in altering the expression of metabolic enzymes so as to favor glycolysis. When stimulated with poly I:C, there is a decline in OCR ( Figure 3C ). Concurrently, there is a documented rise in ECAR ( Figures 1C,  3A, and 3B) . Whereas the rise in ECAR was substantial, the rise in lactate production was modest ( Figure 3E ). The additional increment in ECAR was likely attributable to the mitochondrial protons that are cotransported with citrate into the cytoplasm, in exchange for malate. 34 Taken together, innate immune signaling induces a glycolytic switch in human fibroblasts, where some pyruvate is diverted from fueling the TCA cycle (and is rather converted to lactate), and some citrate is diverted from the TCA cycle and is converted to acetylcoA to support the increase in histone acetylation. The glycolytic shift induced by activation of innate immune signaling does not directly induce EC gene expression, but rather favors an open chromatin configuration that facilitates transdifferentiation.
Innate Immune Activation and Nuclear Reprogramming
Whereas endothelial cells are highly glycolytic in comparison with fibroblasts, 35, 36 it might be expected that the transition between these 2 cell types would be associated with a glycolytic shift. However, the glycolytic shift occurred well before iECs were generated. Indeed, fibroblasts underwent a glycolytic shift on activation of innate immunity, in the absence of endothelial growth factors. These findings are consistent with our previous findings that innate immune activation causes global changes in the activity and expression of epigenetic modifiers, to promote DNA accessibility. 14, 15 This signaling pathway is critical for the nuclear reprogramming that underlies a major cellular transformation. For example, the generation of induced pluripotent stem cells requires the Yamanaka factors to provide directionality, but also requires activation of innate immune signaling to provide the epigenetic plasticity for the Yamanaka factors to exert their effect.
14 Thus, the generation of induced pluripotent stem cells using retroviral vectors encoding the Yamanaka factors can be abrogated by knockdown of the relevant pattern recognition receptors, TLR3 and Rig-like receptors. 14, 37 The transdifferentiation of fibroblasts to iECs also requires activation of innate immune signaling, and is antagonized by knockdown of TLR3. 15 In addition to changes in the expression of epigenetic modifiers, the effect of innate immune A, ACL specific inhibitors BMS303141 and SB204990 decreased transdifferentiation yield (n=3). B, ACL siRNA impaired transdifferentiation efficiency (n=3). C, ACL knockdown reduced the effect of poly I:C to induce glycolysis as reflected by ECAR measured by Seahorse assay (n=3). D, LDHA inhibitor reduces the nuclear level of ACL induced by poly I:C (n=3). E, Schematic model of the control of glycolytic switch in transdifferentiation. Innate immune signaling induces a glycolytic switch and glucose is used to generate lactate or citrate; the latter is transported to the nucleus. There, it will be converted into acetyl-coA by ACL, and to support histone acetyl-coA and transdifferentiation (*0.01<P<0.05; **0.001<P<0.01 16 This phenomenon, whereby activation of innate immunity increases epigenetic plasticity to permit phenotypic fluidity, is termed transflammation.
The major source of nitric oxide in mature endothelial cells is endothelial NOS. However, this isoform of NOS, does not play a role in transdifferentiation, because we do not observe endothelial NOS expression in the transdifferentiating cells until very late in the process. Accordingly, the effect of endothelial NOS to enhance glycolysis (by generating nitric oxide that competes with cellular oxygen at cytochrome C) is not a factor in transdifferentiation. By contrast, inducible NOS expression occurs early in transdifferentiation. 15 The early induction of inducible NOS, in association with global changes in transcriptional profile and epigenetic markings appears to be mediated by the known transcriptional effectors of innate immune signaling, eg, NF-κB and IRF3.
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Metabolism and Epigenetic Plasticity
Acetyl-CoA plays a central role in metabolism as shown in the schematic in Figure VII in the online-only Data Supplement, and in phenotypic modulation, as well. For example, activation of macrophages and dendritic cells (DCs) is associated with a glycolytic switch, which increases the accumulation of citrate and succinate. Succinate activates hypoxia-inducible factor-1α to promote inflammatory gene expression. Citrate is exported from the mitochondria to undergo cytosolic metabolism to acetyl-CoA for both fatty acid synthesis and protein acetylation, both of which are linked to macrophage and DC activation. Interference with glycolysis abolishes the ability of DCs to activate T cells. 38, 39 Other mitochondrial metabolites influence transcriptional and epigenetic regulation. 40, 41 For example, α-ketoglutarate, one of the intermediary metabolites of the TCA cycle, and also very important for glutamine metabolism, is a required cofactor and activator for the ten-eleven translocation (TET) enzymes and Jumonji C domain-containing (JMJD) dependent DNA or histone demethylases. 42 It is also an essential cofactor required to suppress hypoxia-inducible factor expression under normoxia. 43 It is possible that other metabolic pathways such as those mediating glycogen storage could potentially affect cell fate determination, a question worthy of further exploration.
We did not perform single-cell profiling of the metabolic state of the iECs that we derived from our protocol. It is possible that there is heterogeneity in the metabolic profile of the iECs that could have physiological consequences. For example, the endothelium of some tumors are heterogeneous in their metabolic state, which is associated with increased vascular permeability. 35 It is also possible that metabolic heterogeneity in our starting population of fibroblasts could underlie the low yield of transdifferentiation. In future studies, single-cell transcriptional and metabolic profiling may address these unknowns.
In this article, we show that poly I:C activation of innate immunity increases the glucose-derived citrate level, and the expression of the mitochondrial citrate transporter Scl25a1, as well. The resulting increase in intracellular citrate would provide the substrate for acetyl-CoA production by ACL, which is essential for lipid metabolism and which plays a role in tumor growth and progression. 44, 45 Cytosolic citrate converted to acetyl-CoA via ACL is often involved in lipid synthesis. However, we observed no change in cytoplasmic fat concentrations by Nile red staining ( Figure VA in the online-only Data Supplement) after poly I:C treatment, and cytosolic ACL protein levels were also unchanged. In addition, other sources for nuclear conversion of acetyl-CoA, ACSS2, 46 and PDH 27 appear uninvolved in our system. Rather, we observed an increase in nuclear ACL that converts citrate into acetyl-CoA to support the observed increase in histone acetylation, ie, H3K9ac, H3K27ac, and H3K14ac histone markings that promote DNA accessibility.
Our results are the first to show that a glycolytic shift is required for transdifferentiation. This glycolytic shift is accompanied by an increase in the mitochondrial export of citrate. Furthermore, we document an increase in nuclear ACL, which converts citrate to acetyl-CoA, thereby supporting the observed increase in histone acetylation. Thus, metabolism is coupled to epigenetic control of reprogramming. Future work to elucidate the metabolic communication between the mitochondria and the nucleus will facilitate an understanding of transdifferentiation and facilitate its therapeutic application.
